PMID- 29520964
OWN - NLM
STAT- MEDLINE
DCOM- 20190116
LR  - 20190116
IS  - 1879-0844 (Electronic)
IS  - 1388-9842 (Linking)
VI  - 20
IP  - 5
DP  - 2018 May
TI  - Type 2 diabetes mellitus and heart failure: a position statement from the Heart 
      Failure Association of the European Society of Cardiology.
PG  - 853-872
LID - 10.1002/ejhf.1170 [doi]
AB  - The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either 
      with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% 
      of patients) and associated with a higher risk of HF hospitalization, all-cause 
      and cardiovascular (CV) mortality. The most important causes of HF in T2DM are 
      coronary artery disease, arterial hypertension and a direct detrimental effect of 
      T2DM on the myocardium. T2DM is often unrecognized in HF patients, and vice 
      versa, which emphasizes the importance of an active search for both disorders in 
      the clinical practice. There are no specific limitations to HF treatment in T2DM. 
      Subanalyses of trials addressing HF treatment in the general population have 
      shown that all HF therapies are similarly effective regardless of T2DM. 
      Concerning T2DM treatment in HF patients, most guidelines currently recommend 
      metformin as the first-line choice. Sulphonylureas and insulin have been the 
      traditional second- and third-line therapies although their safety in HF is 
      equivocal. Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor 
      dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization. 
      Indeed, a DPP4 inhibitor, saxagliptin, has been associated with a higher risk of 
      HF hospitalization. Thiazolidinediones (pioglitazone and rosiglitazone) are 
      contraindicated in patients with (or at risk of) HF. In recent trials, 
      sodium-glucose co-transporter-2 (SGLT2) inhibitors, empagliflozin and 
      canagliflozin, have both shown a significant reduction in HF hospitalization in 
      patients with established CV disease or at risk of CV disease. Several ongoing 
      trials should provide an insight into the effectiveness of SGLT2 inhibitors in 
      patients with HFrEF and HFpEF in the absence of T2DM.
CI  - (c) 2018 The Authors. European Journal of Heart Failure (c) 2018 European Society of 
      Cardiology.
FAU - Seferovic, Petar M
AU  - Seferovic PM
AD  - University of Belgrade School of Medicine, Belgrade University Medical Center, 
      Belgrade, Serbia.
FAU - Petrie, Mark C
AU  - Petrie MC
AD  - Institute of Cardiovascular and Medical Sciences, British Heart Foundation 
      Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
FAU - Filippatos, Gerasimos S
AU  - Filippatos GS
AD  - Department of Cardiology, National and Kapodistrian University of Athens Medical 
      School, Athens University Hospital "Attikon", Athens, Greece.
FAU - Anker, Stefan D
AU  - Anker SD
AD  - Division of Cardiology and Metabolism - Heart Failure, Cachexia & Sarcopenia, 
      Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative 
      Therapies (BCRT); Deutsches Zentrum fur Herz-Kreislauf-Forschung (DZHK) Berlin; 
      Charite Universitatsmedizin Berlin, Germany; Department of Cardiology and 
      Pneumology, University Medicine Gottingen, Gottingen, Germany.
FAU - Rosano, Giuseppe
AU  - Rosano G
AD  - Department of Medical Sciences, IRCCS San Raffaele Pisana, Roma, Italy and 
      Cardiovascular and Cell Science Institute, St George's University of London, 
      London, UK.
FAU - Bauersachs, Johann
AU  - Bauersachs J
AD  - NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, 
      UK.
FAU - Paulus, Walter J
AU  - Paulus WJ
AD  - Department of Physiology and Institute for Cardiovascular Research VU, VU 
      University Medical Center, Amsterdam, The Netherlands.
FAU - Komajda, Michel
AU  - Komajda M
AD  - Institute of Cardiometabolism and Nutrition (ICAN), Pierre et Marie Curie 
      University, Paris VI, La Pitie-Salpetriere Hospital, Paris, France.
FAU - Cosentino, Francesco
AU  - Cosentino F
AD  - Cardiology Unit, Department of Medicine, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - de Boer, Rudolf A
AU  - de Boer RA
AD  - University of Groningen, University Medical Centre Groningen, Department of 
      Cardiology, Hanzeplein Groningen, The Netherlands.
FAU - Farmakis, Dimitrios
AU  - Farmakis D
AD  - Institute of Cardiovascular and Medical Sciences, British Heart Foundation 
      Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
FAU - Doehner, Wolfram
AU  - Doehner W
AD  - Charite - Campus Virchow (CVK), Center for Stroke Research, Berlin, Germany.
FAU - Lambrinou, Ekaterini
AU  - Lambrinou E
AD  - Department of Nursing, Cyprus University of Technology, Limassol, Cyprus.
FAU - Lopatin, Yuri
AU  - Lopatin Y
AD  - Volgograd Medical University, Cardiology Centre, Volgograd, Russian Federation.
FAU - Piepoli, Massimo F
AU  - Piepoli MF
AD  - Heart Failure Unit, Cardiac Department, Guglielmo da Saliceto Hospital, AUSL, 
      Piacenza, Italy.
FAU - Theodorakis, Michael J
AU  - Theodorakis MJ
AD  - Endocrinology, Metabolism and Diabetes Unit, Evgenideion Hospital, University of 
      Athens, Athens, Greece.
FAU - Wiggers, Henrik
AU  - Wiggers H
AD  - Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Lekakis, John
AU  - Lekakis J
AD  - Institute of Cardiovascular and Medical Sciences, British Heart Foundation 
      Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
FAU - Mebazaa, Alexandre
AU  - Mebazaa A
AD  - University Paris Diderot, Paris, France; and Department of Anaesthesia and 
      Critical Care, University Hospitals Saint Louis-Lariboisiere, Paris, France.
FAU - Mamas, Mamas A
AU  - Mamas MA
AD  - Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK.
FAU - Tschope, Carsten
AU  - Tschope C
AD  - Department of Cardiology, Campus Virchow Klinikum, Charite - Universitaetsmedizin 
      Berlin, Berlin, Germany.
FAU - Hoes, Arno W
AU  - Hoes AW
AD  - Julius Center for Health Sciences and Primary Care, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Seferovic, Jelena P
AU  - Seferovic JP
AD  - Clinic of Endocrinology, Diabetes and Metabolic Diseases, Belgrade University 
      Medical Center, Belgrade, Serbia.
FAU - Logue, Jennifer
AU  - Logue J
AD  - Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, 
      UK.
FAU - McDonagh, Theresa
AU  - McDonagh T
AD  - Department of Cardiology, King's College Hospital, Denmark Hill, London, UK.
FAU - Riley, Jillian P
AU  - Riley JP
AD  - National Heart and Lung Institute Imperial College London, London, UK.
FAU - Milinkovic, Ivan
AU  - Milinkovic I
AD  - University of Belgrade School of Medicine, Belgrade University Medical Center, 
      Belgrade, Serbia.
FAU - Polovina, Marija
AU  - Polovina M
AD  - University of Belgrade School of Medicine, Belgrade University Medical Center, 
      Belgrade, Serbia.
FAU - van Veldhuisen, Dirk J
AU  - van Veldhuisen DJ
AD  - Department of Cardiology, University Medical Center Groningen, University of 
      Groningen, Groningen, The Netherlands.
FAU - Lainscak, Mitja
AU  - Lainscak M
AD  - Department of Internal Medicine, and Department of Research and Education, 
      General Hospital Murska Sobota, Murska Sobota, Slovenia.
FAU - Maggioni, Aldo P
AU  - Maggioni AP
AD  - Research Center of the Italian Association of Hospital Cardiologists, Florence, 
      Italy.
FAU - Ruschitzka, Frank
AU  - Ruschitzka F
AD  - University Heart Centre, University Hospital Zurich, Zurich, Switzerland.
FAU - McMurray, John J V
AU  - McMurray JJV
AD  - British Heart Foundation, Glasgow Cardiovascular Research Centre, Institute of 
      Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180308
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
SB  - IM
MH  - *Cardiology
MH  - Comorbidity/trends
MH  - Diabetes Mellitus, Type 2/*epidemiology
MH  - Europe
MH  - Global Health
MH  - Heart Failure/*epidemiology
MH  - Humans
MH  - Prevalence
MH  - *Societies, Medical
MH  - Survival Rate/trends
OTO - NOTNLM
OT  - Glucose-lowering agents
OT  - Heart failure
OT  - Heart failure hospitalization
OT  - Heart failure treatment
OT  - Type 2 diabetes mellitus
EDAT- 2018/03/10 06:00
MHDA- 2019/01/17 06:00
CRDT- 2018/03/10 06:00
PHST- 2017/12/05 00:00 [received]
PHST- 2018/01/23 00:00 [revised]
PHST- 2018/02/02 00:00 [accepted]
PHST- 2018/03/10 06:00 [pubmed]
PHST- 2019/01/17 06:00 [medline]
PHST- 2018/03/10 06:00 [entrez]
AID - 10.1002/ejhf.1170 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2018 May;20(5):853-872. doi: 10.1002/ejhf.1170. Epub 2018 Mar 
      8.